Royalty Pharma plc (NASDAQ: RPRX) Stock Competitors & Peer Comparison
See RPRX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RPRX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RPRX | $58.44 | +0.05% | 25.9B | 11.13 | $5.25 | +1.57% |
| CORT | $113.76 | +3.15% | 12.3B | 325.03 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $78.13 | +1.15% | 6B | 80.55 | $0.97 | N/A |
| LQDA | $66.43 | -0.67% | 5.9B | 48.49 | $1.37 | N/A |
| PBH | $46.80 | +4.07% | 2.2B | 10.59 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $21.11 | -6.39% | 1.3B | -11.41 | -$1.85 | N/A |
| HELP | $13.66 | +10.43% | 846.7M | -3.28 | -$4.16 | N/A |
Stock Comparison
Corcept Therapeutics Incorporated (NASDAQ: CORT)
RPRX vs CORT Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while CORT trades at $113.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas CORT's P/E ratio is 325.03. In terms of profitability, RPRX's ROE is +0.12%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RPRX is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
RPRX vs WBA Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas WBA's P/E ratio is -1.64. In terms of profitability, RPRX's ROE is +0.12%, compared to WBA's ROE of -0.57%. Regarding short-term risk, RPRX is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
RPRX vs KNSA Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while KNSA trades at $78.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas KNSA's P/E ratio is 80.55. In terms of profitability, RPRX's ROE is +0.12%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, RPRX is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
RPRX vs LQDA Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, LQDA has a market cap of 5.9B. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while LQDA trades at $66.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas LQDA's P/E ratio is 48.49. In terms of profitability, RPRX's ROE is +0.12%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, RPRX is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
RPRX vs PBH Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, PBH has a market cap of 2.2B. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while PBH trades at $46.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas PBH's P/E ratio is 10.59. In terms of profitability, RPRX's ROE is +0.12%, compared to PBH's ROE of +0.09%. Regarding short-term risk, RPRX is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
RPRX vs HROWL Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas HROWL's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, RPRX is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
RPRX vs HROWM Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas HROWM's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, RPRX is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
RPRX vs LTGO Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while LTGO trades at $21.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas LTGO's P/E ratio is -11.41. In terms of profitability, RPRX's ROE is +0.12%, compared to LTGO's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check LTGO's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
RPRX vs HELP Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, HELP has a market cap of 846.7M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while HELP trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas HELP's P/E ratio is -3.28. In terms of profitability, RPRX's ROE is +0.12%, compared to HELP's ROE of -0.71%. Regarding short-term risk, RPRX is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
RPRX vs SVA Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas SVA's P/E ratio is -5.68. In terms of profitability, RPRX's ROE is +0.12%, compared to SVA's ROE of -0.01%. Regarding short-term risk, RPRX is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check SVA's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
RPRX vs ETRA Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, ETRA has a market cap of 295.3M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while ETRA trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas ETRA's P/E ratio is -5.25. In terms of profitability, RPRX's ROE is +0.12%, compared to ETRA's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check ETRA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
RPRX vs CUVL Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, CUVL has a market cap of 293.5M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while CUVL trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas CUVL's P/E ratio is 12.56. In terms of profitability, RPRX's ROE is +0.12%, compared to CUVL's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
RPRX vs CELG-RI Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, CELG-RI has a market cap of 254.5M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
RPRX vs HITI Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, HITI has a market cap of 231.1M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while HITI trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas HITI's P/E ratio is -9.71. In terms of profitability, RPRX's ROE is +0.12%, compared to HITI's ROE of -0.36%. Regarding short-term risk, RPRX is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check HITI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
RPRX vs CTOR Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, CTOR has a market cap of 97.2M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while CTOR trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas CTOR's P/E ratio is -2.22. In terms of profitability, RPRX's ROE is +0.12%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, RPRX is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
RPRX vs ATLN Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas ATLN's P/E ratio is -0.68. In terms of profitability, RPRX's ROE is +0.12%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, RPRX is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check ATLN's competition here
Stablecoin Development Corp. (AMEX: SDEV)
RPRX vs SDEV Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, SDEV has a market cap of 49.1M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while SDEV trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas SDEV's P/E ratio is -0.17. In terms of profitability, RPRX's ROE is +0.12%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, RPRX is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
RPRX vs RAD Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas RAD's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to RAD's ROE of +2.76%. Regarding short-term risk, RPRX is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
RPRX vs GLTO Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas GLTO's P/E ratio is -1.78. In terms of profitability, RPRX's ROE is +0.12%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, RPRX is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
RPRX vs NSRX Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, NSRX has a market cap of 29.6M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while NSRX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas NSRX's P/E ratio is -4.78. In terms of profitability, RPRX's ROE is +0.12%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, RPRX is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
RPRX vs SCYX Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, SCYX has a market cap of 27.7M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while SCYX trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas SCYX's P/E ratio is -1.29. In terms of profitability, RPRX's ROE is +0.12%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, RPRX is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
RPRX vs COSM Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, COSM has a market cap of 18.4M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while COSM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas COSM's P/E ratio is -0.46. In terms of profitability, RPRX's ROE is +0.12%, compared to COSM's ROE of -1.19%. Regarding short-term risk, RPRX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check COSM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
RPRX vs BFRI Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, BFRI has a market cap of 14.9M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while BFRI trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas BFRI's P/E ratio is -2.11. In terms of profitability, RPRX's ROE is +0.12%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, RPRX is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
RPRX vs CNSY Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, CNSY has a market cap of 13.1M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while CNSY trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas CNSY's P/E ratio is -0.45. In terms of profitability, RPRX's ROE is +0.12%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, RPRX is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CNSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
RPRX vs SCNX Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, SCNX has a market cap of 12.4M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while SCNX trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas SCNX's P/E ratio is -0.15. In terms of profitability, RPRX's ROE is +0.12%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, RPRX is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SCNX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
RPRX vs BFRIW Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, BFRIW has a market cap of 11.6M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, RPRX's ROE is +0.12%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, RPRX is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check BFRIW's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
RPRX vs CJJD Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas CJJD's P/E ratio is -0.46. In terms of profitability, RPRX's ROE is +0.12%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, RPRX is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
RPRX vs SSY Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas SSY's P/E ratio is -2.86. In terms of profitability, RPRX's ROE is +0.12%, compared to SSY's ROE of -0.09%. Regarding short-term risk, RPRX is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
RPRX vs POM Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while POM trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas POM's P/E ratio is -0.13. In terms of profitability, RPRX's ROE is +0.12%, compared to POM's ROE of +0.16%. Regarding short-term risk, RPRX is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
RPRX vs BGMS Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, BGMS has a market cap of 5.3M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while BGMS trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas BGMS's P/E ratio is -0.27. In terms of profitability, RPRX's ROE is +0.12%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, RPRX is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BGMS's competition here
Eocene Ltd. (NASDAQ: EOCN)
RPRX vs EOCN Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, EOCN has a market cap of 3.6M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while EOCN trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas EOCN's P/E ratio is -0.25. In terms of profitability, RPRX's ROE is +0.12%, compared to EOCN's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
RPRX vs PAVS Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while PAVS trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas PAVS's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, RPRX is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
RPRX vs MDVL Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas MDVL's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, RPRX is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
RPRX vs ATNFW Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas ATNFW's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, RPRX is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
RPRX vs BGMSP Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, RPRX's ROE is +0.12%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, RPRX is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
RPRX vs AZNH Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas AZNH's P/E ratio is 38.35. In terms of profitability, RPRX's ROE is +0.12%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, RPRX is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
RPRX vs LFLYW Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, RPRX's ROE is +0.12%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, RPRX is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
RPRX vs PRPH Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, PRPH has a market cap of 148.9K. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas PRPH's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, RPRX is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
RPRX vs CPD Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, CPD has a market cap of 0. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas CPD's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to CPD's ROE of N/A. Regarding short-term risk, RPRX is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check CPD's competition here
POZEN Inc. (NASDAQ: POZN)
RPRX vs POZN Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, POZN has a market cap of 0. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas POZN's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to POZN's ROE of +0.61%. Regarding short-term risk, RPRX is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check POZN's competition here
Shire plc (NASDAQ: SHPG)
RPRX vs SHPG Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas SHPG's P/E ratio is 11.35. In terms of profitability, RPRX's ROE is +0.12%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, RPRX is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check SHPG's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
RPRX vs OREX Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, OREX has a market cap of 0. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas OREX's P/E ratio is -0.14. In terms of profitability, RPRX's ROE is +0.12%, compared to OREX's ROE of -0.54%. Regarding short-term risk, RPRX is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check OREX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
RPRX vs IPXL Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas IPXL's P/E ratio is -10.11. In terms of profitability, RPRX's ROE is +0.12%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, RPRX is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check IPXL's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
RPRX vs ESRX Comparison September 2026
Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPRX stands at 25.9B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, RPRX is priced at $58.44 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPRX currently has a P/E ratio of 11.13, whereas ESRX's P/E ratio is 10.69. In terms of profitability, RPRX's ROE is +0.12%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, RPRX is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check ESRX's competition here